Tradestie Institutional Equity Comparison Engine

MDGL vs SYRE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SYRE Overall Edge

SYRE Captures Institutional Edge (3โ€“1 Pillars ยท 3โ€“7 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while MDGL counters with relative strength in Valuation. Fundamentally, MDGL trades at 38.1x Forward P/E with -10.7% operating margin (+50.1% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MDGL sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MDGL
MDGL 38.1x vs SYRE N/M Fwd P/E
Growth & Margin Winner SYRE
Op Margin -10.7% vs 0.0% ยท YoY +50.1% vs +0.0%
Momentum & Technical Winner SYRE
1Y -17.8% vs +341.7% ยท 52W Pos 27% vs 88%
Options & Structure Winner SYRE
CONSOLIDATION (13th %ile IV) vs UNCLASSIFIED (10th %ile IV)
MDGL NASDAQ
Madrigal Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$423.54
-0.9% 1D
Market Cap $9.8B
1M Return -5.83%
1Y Return -17.75%
Forward P/E 38.1x
Unified AI Score
47.6 / 100 HOLD
Tech 53.0 Fund 63.0 Flow 63.0 Mom 50.0
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MDGL -17.75% SYRE +341.74% Spread: +359.49 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MDGL TTM Op. Margin: -10.7% SYRE TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDGL vs SYRE. Trailing 12-month operating profitability (MDGL -10.7% vs SYRE 0.0%) and valuation multiples (MDGL 38.1x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MDGL (7) vs SYRE (3)
Institutional Metric MDGL SYRE Criterion Row Winner
Market Capitalization Scale $9.8B $9.8B Larger Scale MDGL
Trailing P/E Ratio Valuation 61.4x N/M Lower Multiple MDGL
Forward P/E Ratio Valuation 38.1x N/M Lower Multiple MDGL
Revenue Growth (YoY) Growth +50.1% +0.0% Higher Growth MDGL
Operating Margin (TTM) Profitability -10.7% 0.0% Higher Margin SYRE
Net Profit Margin Profitability -10.9% 0.0% Higher Margin SYRE
Return on Equity (ROE) Capital Efficiency -24.8% -35.0% Higher ROE MDGL
52-Week Range Position Momentum 27% ($354โ€“$615) 88% ($22โ€“$111) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 0.28ฮฒ ยท 49% Vol 1.75ฮฒ ยท 59% Vol Lower Realized Risk MDGL
Unified Institutional Score Composite Signal 47.6 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite MDGL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MDGL vs SYRE Buy Guide
MDGL CONSOLIDATION
157d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live MDGL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MDGL nor SYRE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.